Host immunity plays a central role in the regulation of anti-tumour responses during checkpoint inhibitor therapy (CIT). The mechanisms involved in long lasting remission remain unclear. Animal studies have revealed that the microbiome influences the host immune response. This is supported by human studies linking a higher microbial richness and diversity with enhanced responses to CIT. This review focuses on the role of diet, the microbiome and the microbiome-derived metabolome in enhancing responses to current CIT in solid tissue cancers. The Western diet has been associated with dysbiosis, inflammation and numerous metabolic disorders. There is preliminary evidence that lifestyle factors including a high fibre diet are associated with im...
Three recent studies revealed synergy between immune-checkpoint inhibitors and the microbiome as a n...
The composition of the commensal microbiota has recently emerged as a key element influencing the ef...
One of the greatest challenges in the cancer immunotherapy field is the need to biologically rationa...
Host immunity plays a central role in the regulation of anti-tumour responses during checkpoint inhi...
The immune system plays a key role in cancer suppression. Immunotherapy is widely used as a treatmen...
Cancer immunotherapy with checkpoint blockade has become standard of care treatment for numerous can...
The gut microbiome comprises a diverse array of microbial species that have been shown to dynamicall...
Immune checkpoint inhibitors are novel cancer immunotherapeutics that have demonstrated remarkable s...
Currently, various immunotherapeutic treatments are revolutionizing therapies that treat solid neopl...
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Neverth...
Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been signi...
The human microbiota acts as a diverse source of molecular cues that influence the development and h...
Abstract Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory ...
The introduction of immune checkpoint inhibitors has constituted a major revolution in the treatment...
Exploring the role of the gut microbiome in oncology is gaining more attention, mainly due to its ab...
Three recent studies revealed synergy between immune-checkpoint inhibitors and the microbiome as a n...
The composition of the commensal microbiota has recently emerged as a key element influencing the ef...
One of the greatest challenges in the cancer immunotherapy field is the need to biologically rationa...
Host immunity plays a central role in the regulation of anti-tumour responses during checkpoint inhi...
The immune system plays a key role in cancer suppression. Immunotherapy is widely used as a treatmen...
Cancer immunotherapy with checkpoint blockade has become standard of care treatment for numerous can...
The gut microbiome comprises a diverse array of microbial species that have been shown to dynamicall...
Immune checkpoint inhibitors are novel cancer immunotherapeutics that have demonstrated remarkable s...
Currently, various immunotherapeutic treatments are revolutionizing therapies that treat solid neopl...
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Neverth...
Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been signi...
The human microbiota acts as a diverse source of molecular cues that influence the development and h...
Abstract Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory ...
The introduction of immune checkpoint inhibitors has constituted a major revolution in the treatment...
Exploring the role of the gut microbiome in oncology is gaining more attention, mainly due to its ab...
Three recent studies revealed synergy between immune-checkpoint inhibitors and the microbiome as a n...
The composition of the commensal microbiota has recently emerged as a key element influencing the ef...
One of the greatest challenges in the cancer immunotherapy field is the need to biologically rationa...